CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia

Mulas, Olga;Caocci, Giovanni;
2022-01-01

Abstract

There are chronic myeloid leukemia (CML) patients who show resistance to TKI therapy and are prone to progress to more advanced phases of the disease, and new therapeutic approaches are needed. Our study shows that CML cells are vulnerable to dihydroorotate dehydrogenase (DHODH) inhibition mediated by Meds433, a potent DHODH inhibitor developed by our group.
2022
Inglese
22
Suppl 2
S288
S289
1
Esperti anonimi
internazionale
scientifica
CML
Meds433
chronic myeloid leukemia (CML)
dihydroorotate dehydrogenase
Animals
Apoptosis
Cell Line, Tumor
Cell Proliferation
Humans
Mice
Nucleotides
Pyrimidines
Pyruvic Acid
Transaminases
Uridine
Dihydroorotate Dehydrogenase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
no
266
1 Contributo su Rivista::1.5 Abstract in rivista
info:eu-repo/semantics/article
1.5 Abstract in rivista
open
Houshmand, Mohammad; Vitale, Nicoletta; Orso, Francesca; Cignetti, Alessandro; Molineris, Ivan; Gaidano, Valentina; Sainas, Stefano; Giorgis, Marta; B ...espandi
21
Files in This Item:
File Size Format  
1-s2.0-S2152265022013660-main.pdf

open access

Size 127.85 kB
Format Adobe PDF
127.85 kB Adobe PDF View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie